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ABSTRACT 
Antimicrobial resistance is a serious global threat. There is a global menace of antibiotic resistant “super bug”, though the extent and 
the severity of the problem varies. Resistance hampers therapeutic options and drives clinicians to use newer and more expensive 
drugs. In serious cases, multi-resistance provides no treatment options. To overcome resistance, a continuous supply of new 
antibiotics offers an obvious way; but the pipeline of agents in development by the Pharmaceutical industry is very limited. There is 
an ever-evolving need to develop and evaluate newer alternative strategies for countering a worsening clinical situation to overcome 
resistance and reduce the morbidity and mortality associated with infections caused by antibiotic-resistant bacteria. The widespread 
distribution of Antimicrobial resistance has not been paralleled by the development of newer antimicrobials. This happens due to the 
process of drug discovery and clinical trials of new antimicrobials taking longer time and only a fewer new agents been approved for 
use. In modern era, where obstacles like chemo-resistance and mutations torment medicine, scientists across the world are looking to 
adapt lateral approaches in encountering diseases. 
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INTRODUCTION 
Antimicrobial resistance is a serious global threat. There 
is a global menace of antibiotic resistant “super bug”, 
though the extent and the severity of the problem varies
1, 
2
. Resistance hampers therapeutic options and drives 
clinicians to use newer and more expensive drugs. In 
serious cases, multi-resistance provides no treatment 
options. To overcome resistance, a continuous supply of 
new antibiotics offers an obvious way; but the pipeline 
of agents in development by the Pharmaceutical industry 
is very limited. There is an ever-evolving need to 
develop and evaluate newer alternative strategies for 
countering a worsening clinical situation to overcome 
resistance and reduce the morbidity and mortality 
associated with infections caused by antibiotic-resistant 
bacteria
3, 4
. The widespread distribution of Antimicrobial 
resistance has not been matched up to by the 
development of newer antimicrobials. This occurs 
because the process of drug discovery and clinical trials 
of newer antimicrobials taking longer time and only a 
fewer new agents been approved for use
5
. 
In this review paper, we will briefly focus on novel 
antimicrobial strategies tackling antimicrobial resistance.  
DEVELOPMENT OF NEW 
ANTIMICROBIALS 
Majority of antimicrobial obtained from different natural 
sources tend to cause inhibition of various cellular 
processes viz. DNA replication, cell wall biosynthesis, 
and protein synthesis. However with the increase of 
AMR, the investigation of alternative essential cellular 
processes has been screened, as the drug targets for the 
next progeny of antimicrobials 
6
. For instance, 
bedaquiline is a drug targeting the F0F1 ATP synthase 
7
. 
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Irrespective of architectural conservation of the bc1 
complex in many species, Q203- an optimized 
imidazopyridine amide selectively inhibits the 
respiratory cytochrome bc1 complex in mycobacteria 
similar to bedaquiline 
8
. Another promising strategy for 
antimicrobial activity can be caused by attacking the 
central cell wall division mediator FtsZ, which leads to 
the inhibition of Bacterial cell division. This 
antimicrobial attack can occur either by interfering with 
the normal dynamics and activity of FtsZ during the cell 
cycle. It can also lead to the activation of a protease 
bacterial enzyme to cause destruction of FtsZ, therefore 
inflicting microbe death during a self-
destructive manner 
9
 . 
Another attractive newer site of drug action- an 
asymmetric outer cell membrane in Gram-negative 
bacteria has been observed. This outer membrane is a 
permeability barrier and tends to save the cell from the 
various external stresses and forces like the presence of 
antimicrobials. By interacting with the selected β-barrel 
outer membrane proteins including BamA and LptD, a 
novel macrocyclic peptide, JB-95, shows selective 
disruption of the outer cell membrane of the Gram 
negative bacteria 
10, 11, 12
. Likewise, a target for removal 
of Pathogens is by targeting the bacterial protein 
secretion pathway. Employing the Sec-pathway for 
antimicrobial activity is based on two principles; SecA, 
the energy driven motor protein causing the movement 
of pre-proteins across the membrane and Type I signal 
peptidase enzyme, that leads to removal of signal 
peptide to cause release of mature proteins from the 
cytoplasmic membrane
13
 . Another strategy to overcome 
resistance is by employing them in combination with the 
standard antimicrobial drugs. AMR occurs by: 
inactivation of drug, reduced permeability of the drug, 
change in drug target and increase in the efflux of the 
drug. In response to physiological signals, efflux pumps 
serve important physiological functions
14-17
. Many 
recent researches have tried to revert the resistance 
phenotype of efflux pump activation
18
. Adding efflux 
pump inhibitors partially improved the potency and 
efficacy of the drug in anti-Mycobacterium drug 
therapy
19
. Designing and structuring of compounds with 
β-lactam is a promising approach to the development of 
of metallo-β-lactamase inhibitors such as penicillin 
derivatives, carbapenem derivatives, cephalosporin 
derivatives, etc
20 
. 
DEVELOPMENT OF iCHIP DEVICE 
Procedure to cultivate microorganisms under lab 
conditions remained the same for so many years and a 
large population of these microorganisms failed to grow. 
This is called the Great plate Anomaly which is the 
observation that most of the microbes seen in the 
microscope cannot currently be grown under laboratory 
conditions, some may actually be nonviable, and others 
are viable but non culturable 
21
. The researchers couldn’t 
study the chemicals that were released by these microbes 
which showed antimicrobial activity and which could 
serve as a potential for the synthesis of antibiotics. 
However, many years later, a device was made which 
could grow many samples together. This new device was 
known as iChip. Researchers had to dip this chip in the 
bacterial stock, added with agar, which locked the 
sample inside the secure diffusion membrane, placed in 
a large stock sample from the original environment.  
Every cell then acts as a small diffusion chamber. 
Thousands of new bacteria have now been cultured by 
iChip and development of newer antibiotics for e.g. 
Teixobacctin 
22-26
. 
PEPTIDOMIMETIC ANTIMICROBIALS 
Antimicrobials that occur naturally or can be synthesized 
as antimicrobial peptides (AMPs) could form a basis for 
the development of newer functional classes of 
antimicrobials 
27, 28
. Antimicrobial peptides, being 
selective agents, show their activity on the prokaryotic 
membrane. These cause membrane modifications which 
leads to total membrane disintegration
29, 30, 31
. However, 
the clinical utilization of AMPs has been limited. The 
AMPs show high susceptibility to proteolytic enzymes, 
may cause toxicity due to larger quantities of drug 
needed for therapy and above all cost manufacturing
32
. 
Also other characteristics that may restrict use of AMPs 
include higher protein binding and high clearance 
causing a decreased half life. To overcome these 
limitations, generation of proteolytically resistant 
moieties of natural peptides by complete or partial 
substitution of L-moieties with synthetic or non natural 
D- or B- moieties is been studied. McGrath et al. 
synthesized a newer peptide called as (KLAKLAK)2 
which showed decreased toxicity to the mammalian 
cells
33,34
. 
FimH-INHIBITORS  
Uropathogenic E. coli (UPEC), the organism responsible 
for causing more than 85% of all Urinary tract infections 
have progressively become more resistant to antibiotics. 
AMR is not just restricted to community agents but 
broad spectrum antimicrobials like Beta-lactams and 
fluoroquinolones, thereby causing a therapeutic 
problem
35, 36
. UPEC invades the urinary tract by using 
type 1 pili tipped with the FimH adhesin to attach to 
mannosylated receptors present on the luminal surface of 
the human bladder epithelial cells. Thereby causing the 
process of colonization and invasion of bacteria in the 
bladder. As a part of innate defense mechanism, bladder 
cells can expel UPEC from the epithelial cells, but a 
single bacterial cell can replicate to 104-105 which can 
then combine in a type 1 pilus-dependent manner to 
form an intracellular bacterial community (IBC) within 
the epithelial cell. After IBC mature, bacteria detach 
from the IBC and spread to other neighbouring cells to 
form several further IBCs. FimH is necessary for 
invasion, IBC formation and the capability of bacteria to 
invade and colonise the bladder.  Therefore, agents that 
target the FimH are been developed. In every strain of 
E.Coli, the mannose-binding pocket of FimH is 
composed of amino acid residues. Changes in these 
residues which are same in all strains disrupt mannose 
binding and attenuate virulence 
37
. Basically FimH 
inhibitors were derived from mannosides that consist of 
D-mannose units. FimH inhibitors show excellent 
cellular potency and low molecular weight. Cusumano et 
al. 
38
generated a series of 6 candidates with an aim to 
 Maqbool et al                                                                                                     Journal of Drug Delivery & Therapeutics. 2018; 8(5-s):82-86       
ISSN: 2250-1177                                                                               [84]                                                                             CODEN (USA): JDDTAO 
generate orally available agents which can be a 
therapeutic option to treat and prevent chronic UTI 
39, 40
.
 
QUORUM SENSING APPROACHES 
Management of P. aeruginosa infections involves 
complex fluid and ventilator management, definitive 
surgical debridement and advanced technologies. In 
addition, various antimicrobial agents are also employed 
against antibiotic resistant strains of P. aeruginosa such 
as colisitin. Studies in P. aeruginosa pathogenesis has 
revealed a complex regulatory communication system, 
called as quorum sensing (QS), which is responsible for 
controlling about 10% of P. aeruginosa  genes 
41
. 
Quorum sensing (QS), is a cell-density-dependent 
process, which is based on the release of low-molecular 
weight moieties that co-ordinate gene expression in a 
given cell population 
42
. P. aeruginosa releases moieties, 
in response to high population density, which act as 
specific chemical signals. These chemical signals control 
the synthesis of virulence factors that manifest acute 
infection. The QS regulator termed as multiple virulence 
factor regulator (MvfR) helps in controlling the 
expression of majority acute virulence of P. aeruginosa's 
factors that manifest acute infection in addition to 
several various excreted anthranilic acid derivatives, 
majority of which constitute the 4-hydroxy-2-
akylquinolines (HAQs) family. These HAQs, in 
combination with MvfR, serve in the positive regulation 
of the transcription of two operons which encode 
biosynthesis of the virulence molecules. Que et al. 
43
 
showed the presence of HAQs in necrotic burn tissue, 
fat, pus and liquefied fat and drainage liquid. They 
proposed that by targeting QS using anti-QS inhibitors 
may reduce infections caused by MDR bacteria. Hence 
QS could be a promising drug target for new 
antimicrobials because it controls pathogenesis of 
disease and is evolutionarily conserved among 
pathogenic bacteria
44
.  
NEWER TARGETS FOR THE NEXT 
GENERATION ANTIMICROBIALS FOR 
COMBATING DRUG RESISTANCE 
In today’s world various good potent antimicrobials are 
used. However with the development of antimicrobial 
resistance, these have been rendered almost less 
effective. Mostly they act as bacteriostatic and work 
either by inhibition of protein or cell-wall synthesis. This 
situation stresses on the need for creation and designing 
of newer antimicrobial agents with exploring newer 
targets. 
Targeting bacterial proteins 
Antimicrobials can act on newer bacterial proteins for 
e.g. by inhibiting the enzyme β-ketoacyl-acyl-carrier-
protein synthase I/II which is required for fatty-acid 
biosynthesis in bacteria. One such agent,  Platensimycin  
is in pre-clinical trials which targets enzymes involved 
in the fatty acid biosynthesis
45
. 
Targeting the virulence factors  
Toxin function could be a potential target for virulence 
inhibitors. For instance catalytic activity of B. anthracis 
lethal factor; toxin delivery by blocking various bacterial 
systems such as type II or type III secretion; virulence 
gene expression regulated by virulence gene and 
bacterial attachment to host cells
46
.  
Modulating the host response pathways 
Antimicrobial peptides that activate the adaptive 
immune response to combat infections are produced by 
toll-like receptor activators and modulators. These may 
potentially have an antimicrobial role
47
. 
Therapeutic use of bacteriophages  
Genes can be delivered via delivery bacteriophage that 
can bind and inactivate bacterial DNA for e.g. small, 
acid-soluble protein (SASPs) genes could be delivered to 
S. aureus by a S. aureus-specific delivery bacteriophage; 
this results in the release of SASPs which then bind to 
and cause inactivation of bacterial DNA
48
. 
Antibiotics with bioenhancers 
Bioenhancer tend to increase the systemic availability 
and potency of a drug with which it is administered with. 
The bioenhancer doesn’t possess any pharmacological 
activity of its own at the therapeutic dose used
49
.  It is 
employed to increase the potency and efficacy of the 
commonly used antibiotics. For e.g. Tetracycline with 
non-antibiotic Loperamide, increases the activity of 
tetracycline by enhancing its permeability
50
. 
Novel strategies for antibacterial drug discovery 
Majority of the current traditional approaches for 
antibacterial drug discovery have become saturated. This 
has paved way for the development and exploration of 
newer strategies in antibacterial drug discovery. 
Antimicrobial peptides  
AMPs work by interfering with metabolism, acting on 
cytoplasmic components and causing disruption of cell 
membranes. These work as immunomodulators, increase 
the immunity and therefore serve as newer potential 
therapeutic target. Examples are dermaseptin (from frog 
skin), defensin and crustin (from crustacean family) etc. 
omiganan and pexiganan are the drugs under clinical 
trials in this class
51
. 
Engineering a prodrug  
Employing a prodrug form of a drug, which gets 
transformed into a highly potent drug within the micro-
organism, is another strategy. This can help to bypass 
the common resistance mechanisms and thereby serves 
as a promising avenue for new drug development. 
Engineering hybrid antibacterial drugs  
Combination of two drugs can serve as potential to 
overcome antibiotic resistance. For e.g. Mutilin- 
quinolone hybrid AM-3005 (Type II topoisomerase 
inhibitor + a protein synthesis inhibitor) can cover two 
targets simultaneously
52
. 
Alternative form of drug delivery methods 
Unorthodox forms of drug delivery methods can be 
employed such as treatment of chronic P. aeruginosa 
lung infections in cystic fibrosis patients by using 
inhaled amikacin available as nanoscale liposomal 
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formulation. Advantages of this are biofilm penetration 
and sustained release from liposomes and hence serve as 
alternative form of drug delivery method
53
. 
Herbal derivatives as lead molecules 
 Plant drugs and their derivatives can work as lead 
molecules and play a vital role in new drug discovery 
and development. A recent study of Nautiyala et al. 
observed that 1 hr treatment with medicinal smoke, lead 
to 94% reduction of bacterial counts
54
. 
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